FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:300-306 July 30, 1998 Number 5 Next

	Full Text PDF Editorial by Jabs, D. A. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Long-term treatment with antiviral agents has been shown to prevent recurrences of genital and orofacial herpes simplex virus (HSV) disease, but it is uncertain whether prophylactic treatment can prevent recurrences of ocular HSV disease.

Methods We randomly assigned 703 immunocompetent patients who had had ocular HSV disease within the preceding year to receive 400 mg of acyclovir or placebo orally twice daily. The study outcomes were the rates of development of ocular or nonocular HSV disease during a 12-month treatment period and a 6-month observation period.

Results The cumulative probability of a recurrence of any type of ocular HSV disease during the 12-month treatment period was 19 percent in the acyclovir group and 32 percent in the placebo group (P<0.001). Among the 337 patients with a history of stromal keratitis, the most common serious form of ocular HSV disease, the cumulative probability of recurrent stromal keratitis was 14 percent in the acyclovir group and 28 percent in the placebo group (P=0.005). The cumulative probability of a recurrence of nonocular (primarily orofacial) HSV disease was also lower in the acyclovir group than in the placebo group (19 percent vs. 36 percent, P<0.001). There was no rebound in the rate of HSV disease in the six months after treatment with acyclovir was stopped.

Conclusions After the resolution of ocular HSV disease, 12 months of treatment with acyclovir reduces the rate of recurrent ocular HSV disease and orofacial HSV disease. Long-term antiviral prophylaxis is most important for patients with a history of HSV stromal keratitis, since it can prevent additional episodes and potential loss of vision.

Source Information

Kirk R. Wilhelmus, M.D., M.P.H., Roy W. Beck, M.D., Ph.D., Pamela S. Moke, M.S.P.H., Chandler R. Dawson, M.D., Bruce A. Barron, M.D., Dan B. Jones, M.D., Herbert E. Kaufman, M.D., Natalie Kurinij, Ph.D., R. Doyle Stulting, M.D., Ph.D., Joel Sugar, M.D., Elisabeth J. Cohen, M.D., Robert A. Hyndiuk, M.D., and Penny A. Asbell, M.D., as authors of the study, assume full responsibility for the overall content and integrity of the manuscript.

Address reprint requests to Dr. Roy W. Beck at the Jaeb Center for Health Research, 3010 E. 138th Ave., Suite 9, Tampa, FL 33613.

Full Text of this Article

This article has been cited by other articles:

• Chentoufi, A. A., Binder, N. R., Berka, N., Durand, G., Nguyen, A., Bettahi, I., Maillere, B., BenMohamed, L. (2008). Asymptomatic Human CD4+ Cytotoxic T-Cell Epitopes Identified from Herpes Simplex Virus Glycoprotein B. J. Virol. 82: 11792-11802 [Abstract] [Full Text]  
• Goldblum, D, Bachmann, C, Tappeiner, C, Garweg, J, Frueh, B E (2008). Comparison of oral antiviral therapy with valacyclovir or acyclovir after penetrating keratoplasty for herpetic keratitis. Br. J. Ophthalmol. 92: 1201-1205 [Abstract] [Full Text]  
• Uchoa, U. B. C., Rezende, R. A., Carrasco, M. A., Rapuano, C. J., Laibson, P. R., Cohen, E. J. (2003). Long-term Acyclovir Use to Prevent Recurrent Ocular Herpes Simplex Virus Infection. Arch Ophthalmol 121: 1702-1704 [Abstract] [Full Text]  
• Lairson, D. R., Begley, C. E., Reynolds, T. F., Wilhelmus, K. R. (2003). Prevention of Herpes Simplex Virus Eye Disease: A Cost-effectiveness Analysis. Arch Ophthalmol 121: 108-112 [Abstract] [Full Text]  
• Halberstadt, M, Machens, M, Gahlenbek, K-A, Bohnke, M, Garweg, J G (2002). The outcome of corneal grafting in patients with stromal keratitis of herpetic and non-herpetic origin. Br. J. Ophthalmol. 86: 646-652 [Abstract] [Full Text]  
• Kaufman, H. E. (2002). Can We Prevent Recurrences of Herpes Infections without Antiviral Drugs? The Weisenfeld Lecture. IOVS 43: 1325-1329 [Full Text]  
• Loutsch, J. M., Sainz, B. Jr., Marquart, M. E., Zheng, X., Kesavan, P., Higaki, S., Hill, J. M., Tal-Singer, R. (2001). Effect of Famciclovir on Herpes Simplex Virus Type 1 Corneal Disease and Establishment of Latency in Rabbits. Antimicrob. Agents Chemother. 45: 2044-2053 [Abstract] [Full Text]  
• Carr, D. J.J., Härle, P., Gebhardt, B. M. (2001). The Immune Response to Ocular Herpes Simplex Virus Type 1 Infection. Exp. Biol. Med. 226: 353-366 [Abstract] [Full Text]  
• Koelle, D. M., Reymond, S. N., Chen, H., Kwok, W. W., McClurkan, C., Gyaltsong, T., Petersdorf, E. W., Rotkis, W., Talley, A. R., Harrison, D. A. (2000). Tegument-Specific, Virus-Reactive CD4 T Cells Localize to the Cornea in Herpes Simplex Virus Interstitial Keratitis in Humans. J. Virol. 74: 10930-10938 [Abstract] [Full Text]  
• Herpetic Eye Disease Study Group, (2000). Psychological Stress and Other Potential Triggers for Recurrences of Herpes Simplex Virus Eye Infections. Arch Ophthalmol 118: 1617-1625 [Abstract] [Full Text]  
• Herpetic Eye Disease Study Group, (2000). Oral Acyclovir for Herpes Simplex Virus Eye Disease: Effect on Prevention of Epithelial Keratitis and Stromal Keratitis. Arch Ophthalmol 118: 1030-1036 [Abstract] [Full Text]  
• Tambasco, F. P., Cohen, E. J., Nguyen, L. H., Rapuano, C. J., Laibson, P. R. (1999). Oral Acyclovir After Penetrating Keratoplasty for Herpes Simplex Keratitis. Arch Ophthalmol 117: 445-449 [Abstract] [Full Text]  
• (1998). Preventing Recurrent Ocular Herpes. JWatch Infect. Diseases 1998: 11-11 [Full Text]  
• (1998). Acyclovir Lowers Recurrence of Herpes Eye Infections. JWatch General 1998: 3-3 [Full Text]  
• Jabs, D. A. (1998). Acyclovir for Recurrent Herpes Simplex Virus Ocular Disease. NEJM 339: 340-341 [Full Text]